Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

被引:5
作者
Mueller D. [1 ]
Gandjour A. [2 ]
机构
[1] Institute for Health Economics and Clinical Epidemiology, University Hospital of Cologne (AöR), D-50935 Köln
[2] Pennington Biomedical Research Center, Louisiana State University, Louisiana
关键词
Alendronic-acid; Budget-impact-analysis; Cost-utility; Postmenopausal-; osteoporosis; Radiography;
D O I
10.2165/11587360-000000000-00000
中图分类号
学科分类号
摘要
Background: The aging of the population is likely to increase the number of osteoporosis-related fractures, such as hip fractures, and hence the economic burden for society. Therefore, strategies to identify women at increased risk are of major interest. Objective: The aim of this study was to determine the cost effectiveness of preventive services for osteoporosis, comparing secondary plus tertiary prevention (SP/TP) versus tertiary prevention (TP) alone in post-menopausal women in Germany. Methods: A cost-utility analysis and a budget-impact analysis were performed from the perspective of the German statutory health insurance (SHI). A Markov model simulated costs and benefits discounted at 3% over a lifetime horizon. Results: Cost effectiveness of TP compared with no screening was €669, €477 and €385 per QALY for women aged 60, 70 and 80 years, respectively (year 2010 values). In women aged 50 years, TP dominated no prevention. Cost effectiveness of SP/TP compared with TP was €4543, €19 791, €8670 and €3368 for women aged 50, 60, 70 and 80 years, respectively. SP/TP resulted in additional costs of €109 million or 0.10% of the SHIs annual budget (TP alone = €8 million). Conclusion: Compared with TP, a strategy based on SP/TP appears to be more expensive but more effective in each age group. Given that cost effectiveness seems acceptable, allocation of resources to SP/TP to decrease postmenopausal osteoporotic fracture risk may be justified. © 2011 Adis Data Information BV. All rights reserved.
引用
收藏
页码:259 / 273
页数:14
相关论文
共 70 条
[41]  
(2006)
[42]  
Catalogue of Nonphysician Treatments, (2004)
[43]  
Price Lists, (2004)
[44]  
Fallpauschalen-Katalog, (2006)
[45]  
Abschlussbericht Zur Weiterentwicklung des G-DRGSystems für das Jahr 2004 Klassifikation, Katalog und Bewertungsrelationen Band II: Fallpauschalenkatalog, Klinische Profile, Kostenprofile
[46]  
Krankheitskosten 2002, 2004 und 2006
[47]  
Tosteson A.N.A., Jonsson B., Grima D.T., O'Brien B.J., Black D.M., Adachi J.D., Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions, Osteoporosis International, 12, 10, pp. 849-857, (2001)
[48]  
Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., Wong P.K., Medication compliance and persistence: Terminology and definitions, Value in Health, 11, 1, pp. 44-47, (2008)
[49]  
Tidermark J., Zethraeus N., Svensson O., Tornkvist H., Ponzer S., Femoral neck fractures in the elderly: Functional outcome and quality of life according to EuroQol, Quality of Life Research, 11, 5, pp. 473-481, (2002)
[50]  
Marshall D., Johnell O., Wedel H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, British Medical Journal, 312, 7041, pp. 1254-1259, (1996)